10 completed, 8 terminated, 1 active not recruiting, 1 recruiting. 20 Phase 1, 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 20 | Completed 10, Terminated 8, Active not recruiting 1, Recruiting 1 |
| Phase 2 | 9 | Completed 4, Terminated 3, Active not recruiting 1, Recruiting 1 |
Follow INCB039110: new trials by email Literature Review of INCB039110 trials Research Report on INCB039110
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO) ASTX727, Itacitinib, Ruxolitinib - MDS/MPN | Phase 1 / Phase 2 | Recruiting | Michael Savona | 94 | 2021-11-24 | 2026-10-29 |
| Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome After Donor Hematopoietic Cell Transplant Itacitinib, Itacitinib Adipate - Bronchiolitis Obliterans | Phase 1 | Terminated | M.D. Anderson Cancer Center | 8 | 2021-10-08 | 2025-11-10 |
| Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation Itacitinib - Bronchiolitis Obliterans Syndrome | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 23 | 2020-02-04 | 2025-10-20 |
| Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia Alemtuzumab, Itacitinib - Recurrent T-Cell Prolymphocytic Leukemia, T-Cell Prolymphocytic Leukemia | Phase 1 | Completed | M.D. Anderson Cancer Center | 15 | 2020-01-15 | 2024-10-10 |
| Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects Itacitinib, Corticosteroids - Acute Graft-versus-host Disease | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 2 | 2019-12-31 | 2025-11-04 |
| Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas Itacitinib, Laboratory Biomarker Analysis - Metastatic Leiomyosarcoma, Metastatic Synovial Sarcoma | Phase 1 | Terminated | Fred Hutchinson Cancer Center | 27 | 2019-09-30 | 2024-05-08 |
| INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors. Trametinib, Dabrafenib, INCB039110 - Melanoma | Phase 1 | Terminated | Massachusetts General Hospital | 1 | 2019-05-29 | 2023-09-22 |
| Itacitinib + Everolimus in Hodgkin Lymphoma Itacitinib, Everolimus - Classical Hodgkin Lymphoma | Phase 1 / Phase 2 | Active not recruiting | University of Pennsylvania | 23 | 2019-02-11 | 2026-06-23 |
| Itacitinib in Advanced Hepatocellular Carcinoma Itacitinib - Advanced Hepatocellular Carcinoma | Phase 1 | Completed | Imperial College London | 19 | 2018-12-03 | 2026-05-04 |
| Safety of Itacitinib in Combination With Corticosteroids for Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Japanese Subjects Itacitinib, Corticosteroid - Acute Graft-versus-host Disease | Phase 1 | Completed | Incyte Corporation | 14 | 2018-03-20 | 2020-03-03 |
| GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease Itacitinib, Calcineurin inhibitor - Hematologic Malignancies | Phase 1 | Terminated | Incyte Corporation | 84 | 2018-02-27 | 2025-10-21 |
| A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma itacitinib, ibrutinib - Lymphoma | Phase 1 / Phase 2 | Completed | Incyte Corporation | 33 | 2016-12-29 | 2023-06-15 |
| An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer Itacitinib, Osimertinib - Lung Cancer | Phase 1 / Phase 2 | Completed | Incyte Corporation | 59 | 2016-12-20 | 2026-02-09 |
| A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101) Parsaclisib, Itacitinib, Rituximab - B-Cell Malignancies | Phase 1 / Phase 2 | Completed | Incyte Corporation | 88 | 2016-09-22 | 2023-09-28 |
| Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors Pembrolizumab, itacitinib, INCB050465 - Colorectal Cancer (CRC), Endometrial Cancer | Phase 1 | Completed | Incyte Corporation | 159 | 2016-01-25 | 2022-03-31 |
| Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD Itacitinib (200 mg), Itacitinib (300 mg), prednisone or methylprednisolone (corticosteroids) - Graft-versus-host Disease (GVHD) | Phase 1 | Completed | Incyte Corporation | 31 | 2015-12-01 | 2019-03-08 |
| Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors Itacitinib, Epacadostat, INCB050465 - Solid Tumors | Phase 1 | Terminated | Incyte Corporation | 142 | 2015-11-01 | 2019-09-25 |
| An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies INCB052793, gemcitabine, nab-paclitaxel - Solid Tumors, Advanced Malignancies | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 83 | 2014-09-10 | 2020-04-17 |
| Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies INCB040093, INCB040093 + itacitinib - B-cell Malignancies | Phase 1 | Completed | Incyte Corporation | 121 | 2013-06-30 | 2026-05-11 |
| Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors itacitinib, Gemcitabine, nab-paclitaxel - Solid Tumors, Pancreatic Cancer | Phase 1 / Phase 2 | Completed | Incyte Corporation | 55 | 2013-06-01 | 2019-07-18 |
Graft vs Host Disease (2) · Lung Neoplasms (2) · Melanoma (2) · Neoplasm Metastasis (2) · Pancreatic Neoplasms (2) · Anemia, Refractory, with Excess of Blasts (1) · Breast Neoplasms (1) · Bronchiolitis Obliterans (1) · Bronchiolitis Obliterans Syndrome (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Chondrosarcoma (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Head and Neck Neoplasms (1)
Incyte Corporation (13) · M.D. Anderson Cancer Center (2) · Fred Hutchinson Cancer Center (1) · Imperial College London (1) · Massachusetts General Hospital (1) · Michael Savona (1) · University of Pennsylvania (1)
United States (18) · Spain (3) · France (2) · Italy (2) · United Kingdom (2) · Belgium (1) · Canada (1) · Germany (1) · Japan (1) · South Korea (1) · Taiwan (1)
Rodica Morariu-Zamfir, MD (4) · Peter Langmuir, MD (2) · Albert Assad, M.D. (1) · Amin Alousi, MD (1) · Claudia Corrado, M.D. (1) · David M. Miller, MD, PhD (1) · Ekaterine Asatiani, M.D. (1) · Jakub Svoboda, MD (1) · Kevin O'Hayer, MD (1) · Lance Leopold, MD (1) · Lee Cranmer (1) · Michael Savona, MD (1) · Peter B. Langmuir, MD (1) · Peter Langmuir (1) · Rohini Sharma, Prof. (1)
PMID 29695516, PMID 30115734, PMID 30803990, PMID 32324888, PMID 35288468, PMID 35689489, PMID 38115208, PMID 41536780
2017 (3), 2018 (1), 2019 (1)